Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Update

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) was the target of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 7,700 shares, a growth of 28.3% from the February 28th total of 6,000 shares. Based on an average daily trading volume, of 12,600 shares, the short-interest ratio is currently 0.6 days. Currently, 0.1% of the shares of the company are short sold.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Armata Pharmaceuticals in a report on Thursday, December 19th.

Armata Pharmaceuticals Stock Down 9.7 %

Shares of Armata Pharmaceuticals stock opened at $1.30 on Thursday. Armata Pharmaceuticals has a 12-month low of $1.30 and a 12-month high of $3.85. The stock has a market cap of $47.03 million, a P/E ratio of -0.79 and a beta of 0.87.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.